Here's Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10
Executive Reshuffles: WELL, SLG and LXRX
Express News | Lexicon Appoints Scott Coiante as Chief Financial Officer
Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer
Private Equity Firms Account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Ownership, While Institutions Account for 33%
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)